BR0308753A - Método para produzir pseudo-ilhotas - Google Patents

Método para produzir pseudo-ilhotas

Info

Publication number
BR0308753A
BR0308753A BR0308753-0A BR0308753A BR0308753A BR 0308753 A BR0308753 A BR 0308753A BR 0308753 A BR0308753 A BR 0308753A BR 0308753 A BR0308753 A BR 0308753A
Authority
BR
Brazil
Prior art keywords
islets
producing pseudo
relates
present
diabetes
Prior art date
Application number
BR0308753-0A
Other languages
English (en)
Inventor
Yin Liang
Jian Zhu
Laurel Sweet
James N Livingston
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of BR0308753A publication Critical patent/BR0308753A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Abstract

"MéTODO PARA PRODUZIR PSEUDO-ILHOTAS". A presente invenção refere-se a um método para preparar pseudo-ilhotas. Além disso, a presente invenção também refere-se a métodos para tratar diabetes e distúrbios relacionados com diabetes por administração de compostos identificados pelos métodos descritos neste relatório.
BR0308753-0A 2002-03-22 2003-03-21 Método para produzir pseudo-ilhotas BR0308753A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36672802P 2002-03-22 2002-03-22
PCT/US2003/008712 WO2003082189A2 (en) 2002-03-22 2003-03-21 Method for producing pseudo islets

Publications (1)

Publication Number Publication Date
BR0308753A true BR0308753A (pt) 2005-01-11

Family

ID=28675278

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308753-0A BR0308753A (pt) 2002-03-22 2003-03-21 Método para produzir pseudo-ilhotas

Country Status (12)

Country Link
US (1) US20040005299A1 (pt)
EP (1) EP1490474A4 (pt)
JP (1) JP2005527203A (pt)
KR (1) KR20050000375A (pt)
CN (1) CN1643134A (pt)
AU (1) AU2003215023A1 (pt)
BR (1) BR0308753A (pt)
CA (1) CA2474512A1 (pt)
MX (1) MXPA04007064A (pt)
PL (1) PL372313A1 (pt)
WO (1) WO2003082189A2 (pt)
ZA (1) ZA200408436B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2574424A1 (en) * 2004-07-28 2006-02-02 F. Hoffmann-La Roche Ag Insulin promoter factor 1 as target/marker of beta cell failure
EP2630233B1 (en) * 2010-10-22 2017-03-22 Lifeline Scientific, Inc. Cultured pancreas islets
JP2016202172A (ja) * 2015-04-16 2016-12-08 国立大学法人京都大学 疑似膵島の製造方法
CN109957539A (zh) * 2017-12-14 2019-07-02 深圳先进技术研究院 一种人造胰岛组织及其制备和应用
CN109406769A (zh) * 2018-09-28 2019-03-01 李军 Akr在min6细胞中胰岛素分泌机制研究的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759830A (en) * 1986-11-20 1998-06-02 Massachusetts Institute Of Technology Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo
US6001360A (en) * 1988-12-13 1999-12-14 University Of Florida Method and compositions for early detection and treatment of insulin dependent diabetes mellitus
US6001387A (en) * 1992-05-29 1999-12-14 The Reguents Of The University Of California Spin disk encapsulation apparatus and method of use
US5510263A (en) * 1993-04-05 1996-04-23 Desmos, Inc. Growth of pancreatic islet-like cell clusters
US5876742A (en) * 1994-01-24 1999-03-02 The Regents Of The University Of California Biological tissue transplant coated with stabilized multilayer alginate coating suitable for transplantation and method of preparation thereof
IL113484A0 (en) * 1994-04-28 1995-07-31 Immunex Corp Viral proteins pharmaceutical compositions containing them their preparation and use
US5695998A (en) * 1995-02-10 1997-12-09 Purdue Research Foundation Submucosa as a growth substrate for islet cells
US5679565A (en) * 1995-04-10 1997-10-21 The Regents Of The University Of California Method of preserving pancreatic islets
AU6496996A (en) * 1996-02-23 1997-09-10 Circle Biomedical, Inc. Novel artificial pancreas
MY128450A (en) * 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6864069B2 (en) * 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use

Also Published As

Publication number Publication date
WO2003082189A3 (en) 2003-11-27
US20040005299A1 (en) 2004-01-08
ZA200408436B (en) 2005-10-19
PL372313A1 (en) 2005-07-11
AU2003215023A1 (en) 2003-10-13
CA2474512A1 (en) 2003-10-09
CN1643134A (zh) 2005-07-20
JP2005527203A (ja) 2005-09-15
EP1490474A4 (en) 2005-05-04
EP1490474A2 (en) 2004-12-29
MXPA04007064A (es) 2004-10-29
WO2003082189A2 (en) 2003-10-09
KR20050000375A (ko) 2005-01-03

Similar Documents

Publication Publication Date Title
BRPI0316438B8 (pt) uso de eritropoietina em doenças cardíacas
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
IL221381A0 (en) 2,4-pyrimidinediamine derivatives, their use and methods for their preparation
EA200401365A1 (ru) Способы лечения илеуса
BR0114054A (pt) Método para tratar alergias usando pirazóis substituìdos
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
UA88645C2 (ru) Гетероарильные соединения как бета-миметики для лечения заболеваний дыхательных путей
BG108318A (en) Carboxamide-substituted phenylurea derivatives and method for the production and use thereof as medicaments
CY1111359T1 (el) Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer
BR0308813A (pt) Tratamento de tuberculose usando derivados de pleuromutilina
BR0313792A (pt) Utilização de proteìna de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
WO2009009393A3 (en) Chromium complexes for improvement of memory and cognitive function
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
BR0308753A (pt) Método para produzir pseudo-ilhotas
BR0314540A (pt) Métodos para o tratamento de neurodegeneração
SG156658A1 (en) Treatment of diseases
WO2005047278A3 (de) Substituierte dihydrochinazoline ii
ATE345135T1 (de) Tropan-derivate mit dopamin-wiederaufnahme-hemmer-wirkung für die behandlung von ischämischen erkrankungen
RS20050366A (en) A method for preparing indan-1,3- dicarboxylic acid
ATE267600T1 (de) Mikroemulsionen zur transdermalen verabreichung von apomorphin für die behandlung von morbus parkinson
BR0311761A (pt) Processo para a preparação de 4,6-dicloro-5-fluorpirimidina
FR2870732A1 (fr) Composition pour le traitement de matieres keratiniques comprenantun compose polycarboxylique particulier et un polymere cationique et procedes la mettant en oeuvre

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A, 5A,6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.